Join us in for a breast cancer genomics talk by Stanley Lipkowitz, NCI
By Jeannine Mjoseth
Deputy Communications Chief, NHGRI
On Feb. 3, 2012, Stanley Lipkowitz, M.D., Ph.D., senior investigator in the Laboratory of Cellular and Molecular Biology at the National Cancer Institute (NCI), will present, "An Introduction to Genomics: Breast Cancer Diagnosis and Treatment." His lecture is part of the Genomics in Medicine Lecture Series sponsored by the National Human Genome Research Institute (NHGRI) in collaboration with Suburban Hospital and Johns Hopkins Medical School.
Dr. Lipkowitz will introduce the genomic characterization of breast cancer as currently used in the clinic to define breast cancer subtypes, stratify risk and determine treatment. He will also discuss how genomics are likely to impact the future management of breast cancer. Attendees will learn:
- The types of genomic tests currently in use or being developed for characterization of breast cancer.
- How these tests can be used to characterize breast cancer.
- How these tests can be used to stratify risk and determine treatment.
Each lecture takes place at Suburban Hospital's lower level auditorium at 8600 Old Georgetown Road in Bethesda, Md. All are welcome to the hour-long lectures, which begin at 8 a.m. on the first Friday of the month through June 2012. Refreshments will be served before the lecture and parking is free.
The lectures will be recorded and posted at a later date on GenomeTV, NHGRI's YouTube channel, at www.youtube.com/user/GenomeTV. Advanced registration is not required; however, those requesting continuing medical education (CME) credits are asked to sign in.
Last Reviewed: December 26, 2012
Leave a Comment!
We encourage you to share your thoughts as they relate to the topics being discussed on genome.gov, other websites or discussion forums owned or administered by the National Human Genome Research Institute (NHGRI). We review all comments for posting. We do not discriminate against any views, but we reserve the right not to post comments, or to remove comments, that are inconsistent with our Comment Policy, at our complete discretion.
No comments yet. Be the first!